Anixa Biosciences shares surge 11.11% premarket on positive Phase 1 breast cancer vaccine trial data.

Anixa Biosciences surged 11.11% in premarket trading following the announcement of positive Phase 1 data for its investigational breast cancer vaccine, with primary endpoints met and immune responses confirmed. The company also clarified a poster presentation on its website, reinforcing the clinical progress. While heightened short interest and anticipation of quarterly earnings contributed to pre-existing volatility, the premarket rally was primarily driven by the clinical milestone, which positions the stock for potential investor optimism in its pipeline.